James Hollingshead

James Hollingshead (chief executive) discloses dealings in 2 companies, chiefly ResMed Inc and Insulet Corp. Over a trading history stretching from 21 May 2021 to 28 April 2025, the count stands at 25 filings.

On the open market, the record shows 1 purchase worth €930k and 8 sales worth €4.1M. Taken together, the sales exceed the purchases by €3.1M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 16 share grants.

The latest filing, published on 30 April 2025, reports a share grant of €816k in Insulet Corp. The last insider purchase was made public on 29 August 2023, 1,146 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.